PHA000179_The Lancet

PHA000179_The Lancet

Issue link:

Contents of this Issue


Page 0 of 15 Reprint Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutre, John F Seymour, Talha Munir, Soham D Puvvada, Clemens-Martin Wendtner, Andrew W Roberts, Wojciech Jurczak, Stephen P Mulligan, Sebastian Böttcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari Heitner Enschede, Elisa Cerri, Rod Humerickhouse, Gary Gordon, Michael Hallek, William G Wierda Lancet Oncol 2016; 17: 768–78 Venetoclax: a new weapon to treat high-risk CLL Davide Rossi Lancet Oncol 2016; 17: 690–91 Peer reviewed and fast-tracked to publication in 4 weeks See for WebExtra content Copyright 2016 ELSEVIER LIMITED, 125 London Wall, London EC2Y 5AS, UK. Version verified by CrossMark

Articles in this issue

Links on this page

view archives of PHA000179_The Lancet - PHA000179_The Lancet